Samsung Biologics is paving the way for a more sustainable biopharmaceutical industry. Our approach to sustainability is grounded in accountability, extending beyond emissions reduction to embrace environmental stewardship, social impact, and ethical governance. We are committed to building a more sustainable future in every facet of our operations.
Embedding Sustainability Across the Value Chain
* Market-based emissions: emissions reflecting reductions achieved through market mechanisms, such as renewable energy purchases, which reduce greenhouse emissions because they produce zero emissions.
To meet our net-zero** goal by 2050, Samsung Biologics is implementing a clear roadmap for Scope 1, 2, and 3 emissions. We are driving measurable progress through the data-backed management of energy use, renewable transition rates, and GHG emissions, while reinforcing climate governance across the organization in line with Task Force on Climate-related Financial Disclosures recommendations. Our board of directors, ESG committee, and senior leadership oversee these efforts to ensure company-wide accountability.
** Net zero: a state in which net GHG emissions are reduced to zero by minimizing emissions and offsetting the remainder through absorption or other measures.
Driving a Low-Carbon Supply Chain With Global Partners
As the environmental impact of the supply chain continues to grow, Samsung Biologics is taking proactive steps to help build a decarbonized health care ecosystem. As a champion of the Healthcare Industry’s Supply Chain Working Group under the Sustainable Markets Initiative, we collaborate with global partners to develop practical and scalable strategies for a more sustainable value chain.
We conduct a comprehensive life cycle assessment (LCA) to quantitatively evaluate seven key environmental impact categories, including carbon, water, and resource footprints. Based on these assessments, we measure and manage environmental impacts within our sites and also across the global supply chain. Leveraging our global leadership, we actively collaborate with partners to accelerate the transition toward more sustainable operations.
Sustainability Built into the Design of Our Facilities
At Samsung Biologics, sustainability is embedded from the ground up. In the design and construction of Plant 5, launched in 2025, we adopted over 15,000 ㎡ of low-carbon green concrete, resulting in 50% fewer emissions in the parking lot structure compared to using conventional materials. On-site solar generation now produces 1,163 MWh annually, enhancing energy efficiency and advancing our transition to renewable energy.
To support our RE100 goal by 2050, we are scaling the use of renewable energy through power purchase agreements, renewable energy certificates, and green premium programs. We’re also investing in resource-efficient systems, including reverse osmosis wastewater recycling, RFID(Radio Frequency Identification)-based medical waste tracking, and our internal Green Center, which enables high-efficiency waste sorting and recycling.
A Commitment to Biodiversity and the Future
*LEAP: a framework for natural capital assessment that stands for Locate, Evaluate, Assess, and Prepare.
At Samsung Biologics, environmental preservation is not just a responsibility—it is a core pillar of our sustainability strategy and a business imperative.
Through our Nature Positive roadmap, we are actively working to preserve biodiversity and restore habitats while aligning resource usage with global environmental standards. By taking accountability for the environmental impact of our operations and supply chain, we reaffirm our commitment to future generations.
Driven. For a Sustainable Life.
Sustainable operations are not only about meeting today’s expectations; they are also a lasting promise to future generations. At Samsung Biologics, we are committed to integrating sustainability into every stage of biopharmaceutical development and manufacturing, building a healthier tomorrow one step at a time.
Related Content
Sustainability 2025 ESG Report
Samsung Biologics is paving the way for a more sustainable biopharmaceutical industry. Our approach to sustainability is grounded in accountability, extending beyond emissions reduction to embrace environmental stewardship, social impact, and ethical governance. We are committed to building a more sustainable future in every facet of our operations.
Embedding Sustainability Across the Value Chain
* Market-based emissions: emissions reflecting reductions achieved through market mechanisms, such as renewable energy purchases, which reduce greenhouse emissions because they produce zero emissions.
To meet our net-zero** goal by 2050, Samsung Biologics is implementing a clear roadmap for Scope 1, 2, and 3 emissions. We are driving measurable progress through the data-backed management of energy use, renewable transition rates, and GHG emissions, while reinforcing climate governance across the organization in line with Task Force on Climate-related Financial Disclosures recommendations. Our board of directors, ESG committee, and senior leadership oversee these efforts to ensure company-wide accountability.
** Net zero: a state in which net GHG emissions are reduced to zero by minimizing emissions and offsetting the remainder through absorption or other measures.
Driving a Low-Carbon Supply Chain With Global Partners
As the environmental impact of the supply chain continues to grow, Samsung Biologics is taking proactive steps to help build a decarbonized health care ecosystem. As a champion of the Healthcare Industry’s Supply Chain Working Group under the Sustainable Markets Initiative, we collaborate with global partners to develop practical and scalable strategies for a more sustainable value chain.
We conduct a comprehensive life cycle assessment (LCA) to quantitatively evaluate seven key environmental impact categories, including carbon, water, and resource footprints. Based on these assessments, we measure and manage environmental impacts within our sites and also across the global supply chain. Leveraging our global leadership, we actively collaborate with partners to accelerate the transition toward more sustainable operations.
Sustainability Built into the Design of Our Facilities
At Samsung Biologics, sustainability is embedded from the ground up. In the design and construction of Plant 5, launched in 2025, we adopted over 15,000 ㎡ of low-carbon green concrete, resulting in 50% fewer emissions in the parking lot structure compared to using conventional materials. On-site solar generation now produces 1,163 MWh annually, enhancing energy efficiency and advancing our transition to renewable energy.
To support our RE100 goal by 2050, we are scaling the use of renewable energy through power purchase agreements, renewable energy certificates, and green premium programs. We’re also investing in resource-efficient systems, including reverse osmosis wastewater recycling, RFID(Radio Frequency Identification)-based medical waste tracking, and our internal Green Center, which enables high-efficiency waste sorting and recycling.
A Commitment to Biodiversity and the Future
*LEAP: a framework for natural capital assessment that stands for Locate, Evaluate, Assess, and Prepare.
At Samsung Biologics, environmental preservation is not just a responsibility—it is a core pillar of our sustainability strategy and a business imperative.
Through our Nature Positive roadmap, we are actively working to preserve biodiversity and restore habitats while aligning resource usage with global environmental standards. By taking accountability for the environmental impact of our operations and supply chain, we reaffirm our commitment to future generations.
Driven. For a Sustainable Life.
Sustainable operations are not only about meeting today’s expectations; they are also a lasting promise to future generations. At Samsung Biologics, we are committed to integrating sustainability into every stage of biopharmaceutical development and manufacturing, building a healthier tomorrow one step at a time.
Related Content
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article